| Original language | English |
|---|---|
| Pages (from-to) | 2331 |
| Number of pages | 1 |
| Journal | Journal of the American College of Cardiology |
| Volume | 74 |
| Issue number | 18 |
| DOIs | |
| Publication status | Published - 5 Nov 2019 |
Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver
}
In: Journal of the American College of Cardiology, Vol. 74, No. 18, 05.11.2019, p. 2331.
Research output: Contribution to journal › Letter › peer-review
TY - JOUR
T1 - “Zero”
T2 - The New Superhero or Superhero in Training?
AU - Nambi, Vijay
AU - Virani, Salim S.
AU - Jones, Peter H.
AU - Ballantyne, Christie M.
N1 - Funding Information: Please note: Dr. Nambi has received VA MERIT grant 1I01CX001112-01; .is named on provisional patent no. 61721475 “Biomarkers to Improve Prediction of Heart Failure Risk” filed by Baylor College of Medicine and Roche; and is the site principal investigator for a study sponsored by Merck. Dr. Virani has received research support from the Department of Veterans Affairs Health Services Research and Development (grant IIR 16-072), the World Heart Federation, and the Jooma and Tahir Family; has received an honorarium from the American College of Cardiology in his role as the associate editor for Innovations,acc.org; and is a member of the Steering Committee for the PALM (Patient and Provider Assessment of Lipid Management) at Duke Clinical Research Institute. Dr. Jones is a scientific advisory consultant for Sanofi/Regeneron, Amgen, Amarin, and Esperion. Dr. Ballantyne has received National Institutes of Health grant R01HL134320; has received grants or research support (to his institution) from Abbott Diagnostic, Akcea, Amgen, Esperion, Novartis, Regeneron, and Roche Diagnostic; is a consultant for Abbott Diagnostics, Akcea, Amarin, Amgen, AstraZeneca, Boehringer Ingelheim, Corvidia, Denka Seiken, Esperion, Intercept, Janssen, Matinas BioPharma Inc., Merck, Novartis, Novo Nordisk, Regeneron, Roche Diagnostic, and Sanofi-Synthelabo; and is named on provisional patent no. 61721475 “Biomarkers to Improve Prediction of Heart Failure Risk” filed by Baylor College of Medicine and Roche. The views expressed in this letter are those of the authors and do not necessarily represent the views of the Department of Veterans Affairs.
PY - 2019/11/5
Y1 - 2019/11/5
UR - http://www.scopus.com/inward/record.url?scp=85073607548&partnerID=8YFLogxK
U2 - 10.1016/j.jacc.2019.08.1033
DO - 10.1016/j.jacc.2019.08.1033
M3 - Letter
C2 - 31672196
AN - SCOPUS:85073607548
SN - 0735-1097
VL - 74
SP - 2331
JO - Journal of the American College of Cardiology
JF - Journal of the American College of Cardiology
IS - 18
ER -